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Abstract
Background: The prognosis of glioblastoma remains poor, related to its diffuse spread within the brain. There is an
ongoing search for molecular regulators of this particularly invasive behavior. One approach is to look for actin
regulating proteins that might be targeted by future anti-cancer therapy. The formin family of proteins orchestrates
rearrangement of the actin cytoskeleton in multiple cellular processes. Recently, the formin proteins mDia1 and
mDia2 were shown to be expressed in glioblastoma in vitro, and their function could be modified by small
molecule agonists. This finding implies that the formins could be future therapeutic targets in glioblastoma.
Methods: In cell studies, we investigated the changes in expression of the 15 human formins in primary
glioblastoma cells and commercially available glioblastoma cell lines during differentiation from spheroids to
migrating cells using transcriptomic analysis and qRT-PCR. siRNA mediated knockdown of selected formins was
performed to investigate whether their expression affects glioblastoma migration.
Using immunohistochemistry, we studied the expression of two formins, FHOD1 and INF2, in tissue samples from
93 IDH-wildtype glioblastomas. Associated clinicopathological parameters and follow-up data were utilized to test
whether formin expression correlates with survival or has prognostic value.
Results: We found that multiple formins were upregulated during migration. Knockdown of individual formins
mDia1, mDia2, FHOD1 and INF2 significantly reduced migration in most studied cell lines. Among the studied
formins, knockdown of INF2 generated the greatest reduction in motility in vitro. Using immunohistochemistry, we
demonstrated expression of formin proteins FHOD1 and INF2 in glioblastoma tissues. Importantly, we found that
moderate/high expression of INF2 was associated with significantly impaired prognosis.
Conclusions: Formins FHOD1 and INF2 participate in glioblastoma cell migration. Moderate/high expression of
INF2 in glioblastoma tissue is associated with worse outcome. Taken together, our in vitro and tissue studies
suggest a pivotal role for INF2 in glioblastoma. When specific inhibiting compounds become available, INF2 could
be a target in the search for novel glioblastoma therapies.
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Background
Glioblastoma is the most common primary brain tumor
among adults. The prognosis is poor, mainly due to its
widely infiltrative behavior. At the time of diagnosis,
cancer cells are invariably present within the brain par-
enchyma outside the tumor, frequently as far as in the
contralateral hemisphere [1]. Recent studies have shown
that migrating cells infiltrating the brain express stem
cell markers [2]. Glioblastoma cells that express stem
cell markers are more resistant to radiotherapy and
chemotherapy [3, 4]. Cells outside the tumor bulk may
also be connected by microtubes, forming a network of
infiltrative cells that contribute to this resistance to
treatment [5, 6]. Taken together, these findings suggest
that infiltrating cells may be even more treatment resist-
ant than the tumor bulk. In order to target infiltrating
cells, more knowledge about their cell biology is needed.
Remodeling of the actin cytoskeleton is crucial in cell
migration, mediated by actin-regulating proteins that are
active in different cellular locations. New actin filaments
and networks are formed at the leading edge by actin
nucleating and elongating factors while severing proteins
depolymerize in other cellular locations. Bundling pro-
teins are needed for the formation of contractile actin
stress fibers [7]. The largest group of actin filament nu-
cleating and elongating proteins is the formin family of
proteins, which catalyze the formation of unbranched
actin filaments for both physiological and cancer-
associated processes. The 15 genes encoding formin pro-
teins are differentially expressed in human tissue types
[8]. Individual formins are generally inactive until acti-
vated by Rho GTPases or phosphorylation. They have
diverse biochemical and functional properties in shaping
actin filaments. Their common denominator is the pres-
ence of formin homology 1 (FH1) and formin homology
2 (FH2) domains, with capacity to recruit profilin-bound
actin monomers and add them to growing actin fila-
ments [9].
The aims of this study were, first, to investigate how
the expression of formins is altered in migrating glio-
blastoma cells in an in vitro model, second, to evaluate
the importance of selected formins for migration in
functional studies, and third, to study the expression of
FHOD1 (formin homology domain containing protein 1)
and INF2 (inverted formin 2) in human glioblastoma
specimens.
Methods
Patients and clinical data
Patient-derived cell lines at Turku University Hospital
and the glioma tissue microarrays (TMAs) with patient
follow-up data were established with permission from
the Auria Biobank steering committee and the Hospital
District of Southwest Finland. For cell culture, all
patients had given a written Biobank consent statement.
The samples for TMAs and associated data were ob-
tained as described previously [10], in accordance with
the Finnish Biobank Act (688/2012) which does not re-
quire a separate informed consent from individual
patients.
Transcriptomic analysis
As a pilot study, we utilized data from a transcriptomic
analysis of migrating primary glioblastoma cells com-
pared to cells grown as spheroids from a previous study
[2]. To summarize the experiment the data originated
from, five cell lines (T111, T113, T78, T86 and T87)
were established from glioblastoma tumor samples and
grown in serum free conditions as spheroids. Spheroids
had been plated in a semisolid matrix where part of the
cells differentiated into elongated migrating cells. The
migrating cells had been mechanically separated from
non-migrating cells. RNA from migrating cells and free
floating spheroids had been subjected to array-based
transcriptomic analysis (Affymetrix 133 Plus 2.0 micro-
array). From the normalized data, we extracted the ex-
pression data of all 15 formin genes Formin 1 (FMN1),
Formin 2 (FMN2), Disheveled-associated activator of
morphogenesis 1 (DAAM1), Disheveled-associated acti-
vator of morphogenesis 2 (DAAM2), diaphanous related
formin 1 (mDia1), diaphanous related formin 3 (mDia2),
diaphanous related formin 2 (mDia3), FHOD1, Formin
Homology 2 Domain Containing 3 (FHOD3), Formin-
like protein 1 (FMNL1), Formin-like protein 2 (FMNL2);
Formin-like protein 3 (FMNL3), Delphilin or delta 2-
interacting protein 1 (GRID2IP), Inverted formin 1
(INF1), and INF2 and investigated their expression as
fold-change in migrating cells compared to spheroid
cells. Over 2 fold-change was considered upregulation in
migrating cells.
Cell culture
The commercially available glioblastoma human cell
lines U87, U138 and T98 were from American Type
Culture Collection (Manassas, VA, USA; catalogue num-
bers HTB-14, HTB-16 and CRL-1690, respectively).
U138 and T98 were maintained in DMEM supple-
mented with 10% fetal bovine serum (FBS), 5 mM ultra-
glutamine and 100 U/ml penicillin-streptomycin (Gibco,
CA, USA), while U87 was kept in spheroid medium
(DMEM/F12, 1% B27, 100 U/ml penicillin-streptomycin
(Gibco), 40 ng/ml fibroblast growth factor-2 (FGF-2;
Gibco), and 40 ng/ml epidermal growth factor (EGF;
Invitrogen, CA, USA).
Primary glioblastoma cell cultures established from
glioblastoma samples at Turku University Hospital were
named University of Turku Glioblastoma (UTGB). Fol-
lowing surgical resection, approximately 1–2 g of tumor
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tissue was collected and cultured as described by Rus-
tenhoven et al. [11] From 10 tumor samples, 3 cell lines
were established and tested negative for mycoplasma.
The cell lines had the same mutations as the original
tumor as tested by a 20 gene NGS panel designed for
glioma diagnostics [12]. One cell line did not form
spheroids, and was omitted from further studies. The
clinicopathological characteristics of the two remaining
primary cell lines UTGB4 and UTGB7 are described in
Supplemental Table 1. In addition to these primary cells
lines, we obtained T78, T86, and T87 primary glioblast-
oma cell lines that were included in the transcriptomics
analysis [2]. All cell lines were repeatedly tested for
mycoplasma contamination, and remained negative.
Spheroid formation
Spontaneous spheroid formation was observed for U87,
T86 and UTGB7 cells 3 to 6 days after plating single
cells in spheroid medium. For all the other cell lines,
spheroid formation was achieved using the hanging-drop
technique for 48 h in 6 μl spheroid medium (UTGB4,
4 × 103 cells/drop; T78 and T87, 2 × 103 cells/drop) or
DMEM 10% FBS (T98 and U138, 2 × 103 cells/drop).
Only spheroids with the diameter of 200–600 μm were
used in the experiments.
Cell migration
In order to study if and which formins are up or down-
regulated in migrating cells, spheroids were allowed to
adhere in Geltrex (hESC-Qualified, Ready-To-Use, Re-
duced Growth Factor Basement Membrane Matrix,
Gibco) precoated 6-well plate (30–40 spheroids/well)
during 24 h. Using a microscope, attached spheroids
were separated with the help of a needle and recovered
from the supernatant. Migrated cells were detached with
trypsin-EDTA solution (Sigma-Aldrich), and pelleted by
centrifugation.
qRT-PCR
Total RNA from different fractions was extracted using
NucleoSpin RNA/Protein Kit (Macherey-Nagel, PA,
USA) according to the manufacturer’s protocol and
processed to cDNA with SensiFast cDNA Synthesis Kit
(Bioline, OH, USA). TaqMan qRT-PCR was performed
with a QuantStudio 12 K Flex Real-Time PCR System
(Turku Centre for Biotechnology) using specific primers
(Supplement 1) and quantitation was carried out with
QuantStudio 12 K Flex software using the ΔΔCT
method in order to calculate the relative fold gene ex-
pression. Three replicate samples were studied for detec-
tion of target mRNA expression and GAPDH was used
as an endogenous control. The quantities were expressed
as a fold change relative in migrating cells compared to
immotile spheroids. The results are presented as means.
Transfection with small interfering RNAs, spheroid
migration assay and stainings
The mDia1, mDia2, FHOD1,and INF2 transcripts were
knocked down individually in the commercial cell lines
U87 and U138, and primary glioblastoma cell lines T86
and UTGB7 using 50 nM of SMARTpool small interfer-
ing RNA (siRNA) (Dharmacon Research, Boulder, CA).
Non-targeting Pool siRNA was used as control. Cells at-
tached as monolayer on Geltrex precoated 12-well plates
were transfected using Dharmafect 4 transfection re-
agent (Dharmacon Research) according to the manufac-
turer’s instructions. The knockdown efficacy was
examined 48 h after transfection by western blotting as
described elsewhere [13]. Antibodies, dilutions and
spheroid staining procedures are described in Supple-
ment 1.
Forty-eight hours after siRNA treatment, cells were
trypsinized and plated as drops for spheroid formation
for another 48 h. To analyze migration spheroids were
plated in Geltrex precoated 96-well Image Lock plate
(Essen Bioscience, Ann Arbor, MI) and imaged every 2 h
using the Incucyte S3 incubator system (Essen Bio-
science). Areas of migrated cells and spheroids were
used to indicate migration fold increase related to time
point 1. The experiment was repeated at least 3 times,
with a total of 25–50 spheroids per cell line for each
siRNA treatment. Differences in migration from spher-
oids were analyzed using Student t-test. Two-tailed p
values ≤0.05 were regarded as significant.
Immunohistochemistry of glioblastoma samples
3.5 um sections from TMA:s composed of 1.5 mm cores
of glioma samples were obtained from the Auria Bio-
bank. The cohort includes diffuse glioma samples and
has been previously described in detail [10]. It also in-
cludes relevant clinicopathological parameters and
follow-up data. From this cohort, we analyzed the 93
samples that had an integrated diagnosis of glioblastoma,
IDH-wildtype according to the WHO 2016 classification
[14]. The slides were stained by the streptavidin-
peroxidase method; using a Labvision staining device
(Thermo Fisher Scientific, Fremont, CA) with a Bright
Vision Poly-HRP-anti-mouse/rabbit kit (Immunologic,
Duiven, the Netherlands) as described previously [15].
Briefly, antigen retrieval for INF2 staining was carried
out by microwaving the slides in a pH 9 buffer. Primary
antibody dilutions used were 1:75 for anti-FHOD1
(Sigma-Aldrich, St Louis, MA; catalogue number
HPA024468) and 1:500 for INF2 (Proteintech, Chicago,
IL; catalogue number 20466–1-AP). Furthermore, 10
whole slide samples were evaluated to compare FHOD1
and INF2 expression in tumor bulk to areas of diffuse
tumor cell infiltration in brain tissue. For this, 10 cases
with immunohistochemically detected p53 positivity
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indicating TP53 mutation and representative areas of
solid tumor and diffuse infiltration were selected. The
p53 stainings were performed using Ventana reagents
and a Ventana Benchmark ULTRA autostainer (Ventana
Medical Systems, Tucson, AZ).
Scoring was performed by two pathologists blinded to
clinical data (MG and OC), with 0 standing for negative,
1 for weak, 2 for moderate and 3 for strong staining.
Representative images of staining categories are pre-
sented in Fig. 3.
For survival analyses, both FHOD1 and INF2 stain-
ing scores were dichotomized into low expression
(score 0 or 1) or high expression (score 2 or 3).
Kaplan-Meier with log-rank test and univariate and
multivariate Cox proportional hazards model were
performed to assess survival. Multivariate Cox regres-
sion was analyzed using adjustments for age, pre-
operative Karnofsky Performance Scale (KPS), resec-
tion type, and post-operative adjuvant treatment.
Overall survival (OS) was defined as the time from
surgical resection to death or end of follow-up.
Progression-free survival (PFS) was a composite end-
point defined as the time from surgical resection to
the first tumor progression indicated by re-resection,
start of a new treatment regimen, death, or end of
follow-up. Survival analyses were conducted using
IBM SPSS Statistics version 25.0 for Mac (IBM Corp.,
Armonk, NY).
Results
INF2 and FHOD1 are upregulated in migrating
glioblastoma cells
To investigate the expression profiles of formins in glio-
blastoma, we studied the mRNA expression of all 15 for-
min genes in five different patient-derived glioblastoma
cell lines. The cell lines had been subjected to a spheroid
migration experiment, followed by transcriptomic ana-
lysis of migrating cells and spheroids [2, 16]. The results
are presented in Table 1, as fold-change in migrating
cells as compared to non-migrating cells. None of the
formins was either up- or downregulated in every cell
line. However, seven formins were upregulated upon mi-
gration in one or several cell lines. Of these, FMN2,
DAAM1, DAAM2, mDia3 and FMNL2 were upregulated
in single cell lines. Notably, INF2 and FHOD1 were
widely upregulated 8–141-fold, in three out of five cell
lines. All five cell lines upregulated either INF2 or
FHOD1, or both.
Next, we wanted to test whether formin upregulation
during spheroid migration could be seen in an expanded
set of glioblastoma cell lines by using qRT-PCR. For this
experiment, we included primary glioblastoma cell lines
T78, T86 and T87 (present in transcriptomic analysis)
and UTGB4 as well as UTGB7, which had been estab-
lished at Turku University Hospital. For comparison, we
also included commercially available glioblastoma cell
lines U87, T98 and U138. This time, we compared the
Table 1 Transcriptomic analysis of formin expression in migrating glioblastoma cells compared to cells grown as spheroids. Results
are presented as fold-change in five different primary glioblastoma cell lines T111, T113, T78, T86 and T87. In individual cell lines,
over 2-fold change was observed for seven formins (highlighted as yellow to orange as heatmap)
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mRNA expression profiles of formins between migrating
cells and spheroids plated on Geltrex (all attached). The
results varied between the cell lines, with fold-change of
individual formins varying from 0.1–791.4 (Table 2).
The most commonly upregulated formin was mDia1 (5/
8 cell lines), followed by INF2 (4/8 cells lines). FMN2,
FHOD1, FHOD3, and FMNL1 were found upregulated
in 3/8 cell lines. Six formins were upregulated in 1–2
cell lines each. Cell lines T98 and U138 upregulated
multiple formins. The primary cell lines T78, T86 and
T87 had increased expression of FHOD1 (2/3) and INF2
(3/3). Even though several increases of FHOD1 and
INF2 expression were consistent between microarray
and qRT-PCR results, they were not of similar magni-
tude. With qRT-PCR, the seen upregulation was mainly
2-fold.
Formin knockdown reduces glioblastoma cell migration
The results from the spheroid migration experiments in-
dicate that cells differentiating from spheroids to elon-
gated migrating cells upregulate only selected formins.
Therefore, we decided to study whether the basal ex-
pression of formins FHOD1 and INF2 is necessary for
migration, using siRNA mediated knockdown. As for-
mins mDia1 and mDia2 have earlier been shown to par-
ticipate in glioblastoma migration [17–19], we decided
to include knockdown of these formins in our experi-
ments. The expression of the formins was individually
knocked down in glioblastoma cell lines U87, U138,
T86, and UTGB7. Western blotting was used to check
that knockdown was efficient (Fig. 1a). The targeted pro-
tein level was markedly reduced in a vast majority of the
cell lines.
INF2 and FHOD1 knockdown reduced cell migration
significantly in all four cell lines (15–44%) (Fig. 2a and b,
Supplemental Table 2). The knockdown of mDia1 and
mDia2 had a slighter and more variable effect, with sta-
tistically significant reduction of migration (by 12–30%)
in cell lines U87, U138 and T86, but without significant
effect in cell line UTGB7.
Cell morphology in migrating cells was notably altered
by knockdown of formins. Similar changes were seen in
all cell lines. Representative images of U87 spheroids are
depicted in Fig. 2. INF2, FHOD1 and mDia2 knockdown
resulted in spread cells with a more epithelial appearing
phenotype. With mDia1 knockdown no apparent mor-
phological change was observed as cells maintained their
spindle-like morphology.
High INF2 expression in clinical glioblastoma samples is
associated with worse outcome
To establish whether the most interesting formins from
the transcriptomics analysis, FHOD1 and INF2, are
expressed as protein in human glioblastoma, we per-
formed immunohistochemistry on human glioblastoma
samples. The antibodies used for immunohistochemistry
bind specifically to FHOD1 and INF2. The FHOD1 anti-
body used for immunohistochemistry has previously
Table 2 mRNA expression in migrating glioblastoma cells compared to spheroids. Results are presented as fold-change in five
different primary glioblastoma cell lines and three commercially available cell lines. In individual cell lines, over 2-fold change was
observed for 12 formins shown as different shades of green as heatmap
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been validated by us [20]. The INF2 antibody used was
the same as in Western Blotting, where it detected a
major band of expected size. The band was attenuated
when cells were treated with INF2 siRNA, indicating
specific binding (see Fig. 1a).
In 93 samples of IDH-wildtype glioblastomas, FHOD1
and INF2 expression (scores 1–3) could be detected in
84 and 46% of cases, respectively. Positive staining was
diffusely cytoplasmic (Fig. 3a).
After dichotomization, 18 glioblastomas showed high
expression of FHOD1 (score 2 or 3) and 69 low expres-
sion (score 0 or 1). FHOD1 staining was unsuccessful
for six specimens. For INF2, 18 glioblastomas showed
high expression, 72 low expression, and 3 specimens
were missing.
Survival plots (Fig. 3b-e) show no significant difference
in progression-free survival (PFS) or overall survival
(OS) in glioblastomas according to FHOD1 and INF2
expression, although slightly inferior median PFS and
OS was noted in the INF2 high expression groups (Sup-
plemental Table 3; p values 0.068 and 0.124,
respectively).
In univariate Cox regression analysis, no significant
difference in PFS or OS was observed based on the ex-
pression level of FHOD1 or INF2. Glioblastoma out-
come is highly influenced by several clinicopathological
parameters. Therefore we proceeded with multivariate
analysis. When adjusted for age, pre-operative KPS, re-
section type, and post-operative treatment, high expres-
sion of INF2 was an independent predictor for worse
PFS and OS (Table 3). No difference in survival was ob-
served related to FHOD1 expression.
Expression of formins in TMA samples from the center
of glioblastomas may be different from expression in glio-
blastoma cells infiltrating into the surrounding brain par-
enchyma. To evaluate whether FHOD1 or INF2
expression is altered in areas of diffuse infiltration as com-
pared to solid tumour areas, we studied 10 representative
Fig. 1 Knockdown of mDia1, mDia2, FHOD1, and INF2 expression in U87, U138, and primary glioblastoma cell lines UTGB7 and T86. a The
knockdown efficacy was examined 48 h after transfection by immunoblotting. GAPDH or tubulin was used as a control for protein loading.
Representative immunoblots have been cropped from repeated experiments to save space. The full-length blots are presented in Supplement 2.
b) Representative images from spheroid migration experiment using the T86 primary cell line. Timepoints 0 and 48 h are shown. The edge of
migrating cells is drawn. c) Plots showing fold increase of areas (FI) as a function of time (images were taken every 2 h). Bar graphs highlight the
FI in individual treatment groups at 48 h. Asterisks indicate significant reduction of migration: * p≤ 0.05, ** p≤ 0.01, and *** p≤ 0.001
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glioblastoma samples as whole slides. The cases had
immunohistochemically detected TP53 mutations, which
made it possible for us to firmly differentiate infiltrating
tumor cells from gliosis. In these samples, five glioblast-
omas were found to have diffusely infiltrating cells
expressing moderate/high FHOD1 and/or INF2 in more
than 20% of tumour cells, while the solid tumour showed
absent/low expression (Fig. 4). In five glioblastomas, the
expression of the formins remained unchanged when
comparing infiltrating cells and solid tumour areas. This
result suggests that FHOD1 and INF2 expression is not
necessarily uniform, but can be higher in infiltrating cells
than in tumour bulk.
Discussion
Glioblastoma remains a challenging disease to treat. Al-
though some progress has been made with surgical tech-
niques and combining chemotherapy with radiation, the
wide spread tumour cells combined with resistance to
treatment still signifies dismal prognosis. For a break-
through in glioblastoma treatment, infiltrative cells
within the brain parenchyma should be targeted. There-
fore, effort should be made to characterize the molecular
machinery that defines their behavior. Our approach is
to study proteins that regulate the actin cytoskeleton al-
tering cell shape, adhesion and further directing mem-
brane protrusion force to the leading edge. The actin
cytoskeleton and its regulators could be valid targets for
future therapy.
In this study, we utilized the ability of glioblastoma cell
spheroids to differentiate into elongated migrating cells
as an in vitro model for glioblastoma cell migration.
Herein we report that formin mRNA upregulation in
this event is generally minor, with variation from one
cell line to another.
We found considerable difference in magnitude of
alterations using a transcriptomic array compared to
qRT-PCR. This difference can be attributable to
methodological differences and possibly differences in
laboratory conditions. We were able to validate that
slight upregulation of formins INF2, FHOD1, FHOD3
and mDia1 occurs, which could have some relevance
for migration. However the basal expression of INF2
and FHOD1 may be as important. Both INF2 and
FHOD1 have earlier been found to participate in mi-
gration or invasion and to be upregulated in clinical
cancer tissues in basal-like breast cancer [15], and
FHOD1 has additionally been found expressed in oral
squamous cell carcinoma and melanoma, also with
participation in migration/invasion in vitro [13, 20].
Using a knockdown approach, we could for the first
time show that the expression of INF2 and FHOD1 is
necessary for efficient migration of glioblastoma cells.
This effect was found both in commercial cell lines (U87
and U138) and in a primary glioblastoma cell lines (T86
and UTGB7). Previous studies that have focused on
other formins than INF2 and FHOD1 have also indi-
cated that individual formins participate in glioblastoma
cell migration/invasion. First, a study on formin FHOD3
Fig. 2 Representative pictures of U87 spheroids migration after
treatment with different siRNAs. Spheroids were plated in Geltrex
precoated coverslips and grown for 24 h before they were stained
with phalloidin (green) and DAPI (blue) in order to visualize actin
filaments and nuclei. Morphological changes can be seen after the
knockdown of mDia2, FHOD1, and INF2
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showed that a rapid form of migration induced by lam-
inin tracks was dependent on FHOD3. This was indi-
cated in rat C6 glioma cells and a primary glioma cell
line [21]. Also mDia formins have been shown to partici-
pate in glioblastoma cell migration. mDia activities can
be altered by small molecules, causing either agonism or
antagonism. Of these, agonism has been shown to be
more effective in glioblastoma cell line U87 [18]. Very
recently, Pettee et al. explored the feasibility of mDia
agonism as an anti-invasion strategy in patient-derived
high-grade glioma cells. They found that the molecule
IMM2 efficiently reduced the single cell migration from
the neurosphere core. IMM2 treatment caused a mor-
phologic shift toward ameboid morphology, also inhibit-
ing the formation of microtubes [19]. Microtubes are
recently found cellular extensions in glioblastoma, that
keep glioblastoma cells connected as a network while
migrating [5]. Inhibiting the formation of microtubes
prolongs survival in a mouse model [6]. Although we
did not look for changes in microtubes, our findings
from mDia1 and mDia2 knockdowns were in line with
previous studies. Migration was reduced, confirming ef-
fects seen by others [18]. This was additionally accom-
panied by a shift in morphology with mDia2
knockdown. Migrating glioblastoma cells lost extensions
and mesenchymal morphology, similar to findings re-
ported with IMM2 treatment [19]. Compared to mDia1
and mDia2, we found that FHOD1 knockdown had simi-
lar effect on migration. Importantly, we found clearly
larger reduction of migration upon knockdown of INF2,
Fig. 3 Immunohistochemistry for FHOD1 or INF2 and progression free or overall survival in glioblastoma according to expression level. a)
Immunohistochemistry for FHOD1 (upper panel) and INF2 (lower panel) was performed in tissue from 93 glioblastomas. Staining was scored in
glioblastoma cells as negative = 0, low = 1, moderate = 2, strong = 3. Note that endothelial cells are clearly FHOD1 and INF2 positive in all
categories. Dichotomization was performed by grouping scores 0 and 1 (low expression), and 2 and 3 (high expression). Scale bar: 100 μm. Insets
present details with higher magnification. b, c) Progression-free and overall survival according to FHOD1 expression. d, e) Progression-free and
overall survival according to INF2 expression
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suggesting that modification of its activity could be a
valid target for treatment. To our knowledge there are
currently no available specific inhibitors/agonists for this
formin.
Using immunohistochemistry, we discovered that
formins FHOD1 and INF2 are frequently expressed in
glioblastoma tissue. The level of FHOD1 expression
did not have prognostic significance, but in multivari-
ate analysis cases with moderate/high expression of
INF2 had a worse prognosis than those with absent/
low expression of INF2. This is to the best of our
knowledge the first report on formin protein expres-
sion in a large set of human glioblastoma samples.
We have in previous studies found that FHOD1 is
not expressed in brain parenchyma, although it is
present in endothelial cells in the brain [20]. Accord-
ing to the human protein atlas (www.proteinatlas.org),
INF2 expression is low in glial cells [22]. Therefore,
the moderate/high expression of FHOD1 and INF2 in
a subset of glioblastomas can be considered as over-
expression. However, all glioblastomas did not express
immunohistochemically detectable amounts of these
formins, which suggests that their expression is not
crucial for glioblastoma invasion. It seems likely the
expression profiles of actin regulating proteins vary
from case to other. In other words, the search for
actin-targeting treatment may require a personalized
approach.
Conclusions
Our results indicate that individual formins are up-
regulated as primary glioblastoma cells differentiate
from an immobile spheroid mass to elongated migrat-
ing cells. Contrary to our hypothesis, we could not
identify a single formin that was upregulated in all
cell lines. Instead, primary glioblastoma cell lines
seem to have individual profiles in formin upregula-
tion. This confirms that exploring molecular
Table 3 Multivariate Cox regression model for PFS and OS
Variable PFS OS
HR 95% CI p-value HR 95% CI p-value
Age 1.003 0.98–1.03 0.833 1.002 0.98–1.03 0.853
FHOD1
Low expression 1 1
High expression 1.19 0.57–2.46 0.643 1.0 0.50–2.02 1.000
INF2
Low expression 1 1
High expression 2.33 1.05–5.18 0.038* 2.22 1.04–4.77 0.041*
Pre-operative KPS 0.145 0.019*
100 1 1
90 0.81 0.30–2.12 0.674 0.39 0.15–1.07 0.068
80 1.25 0.48–3.31 0.648 0.75 0.28–2.02 0.568
70 1.29 0.48–3.46 0.619 1.12 0.42–2.98 0.82
60 2.05 0.70–6.02 0.191 1.80 0.62–5.23 0.281
50 1.76 0.56–5.52 0.335 1.38 0.44–4.33 0.583
40 1.55 0.41–5.79 0.516 1.03 0.28–3.88 0.962
30 6.72 1.23–36.85 0.028 5.40 0.99–29.6 0.052
20 1.55 0.30–7.99 0.603 1.51 0.29–7.76 0.623
10 62.8 3.56–1109.3 0.005 39.8 2.28–693.2 0.012
Resection
Gross total 1 1
Subtotal 2.34 1.17–4.69 0.016* 1.69 0.83–3.43 0.151
Post-operative treatment < 0.001** < 0.001**
RT + TMZ 1 1
RT only 2.34 1.22–4.48 0.010 2.47 1.31–4.67 0.005
None 7.34 2.79–19.29 < 0.001 7.97 3.00–21.15 < 0.001
Abbreviations: KPS Karnofsky Performance Scale, RT Radiotherapy, TMZ Temozolomide
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mechanisms in glioblastoma requires more than one
or two cell lines before generalizations can be made.
Although we found that knockdown of several for-
mins reduced migration, the greatest effect was seen
upon INF2 knockdown. Furthermore, moderate/high
expression of INF2 in glioblastoma tissue was associ-
ated with worse outcome. Taken together, our
in vitro and tissue studies suggest a pivotal role for
INF2 in glioblastoma. When specific inhibiting com-
pounds become available, INF2 could be a target in
the search for novel glioblastoma therapies.
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